Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.55 |
| ▸ | ILK | Q13418 | 1/20 | 0.52 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757642 | 0.93 | APP (0.52) | APPILKSULT1A1MAPT | |
| SCHEMBL5756448 | 0.84 | ILK (0.52) | ILK | |
| SCHEMBL5759036 | 0.83 | ILK (0.53) | APPILKMAPT | |
| SCHEMBL5758629 | 0.83 | ILK (0.51) | ILK | |
| SCHEMBL5758909 | 0.79 | ILK (0.55) | APPILK | |
| SCHEMBL5757314 | 0.78 | SULT1A1 (0.52) | APPSULT1A1MAPT | |
| SCHEMBL5756935 | 0.78 | ILK (0.51) | APPILKMAPT | |
| SCHEMBL5755158 | 0.78 | ILK (0.51) | APPILKSULT1A1 | |
| SCHEMBL5755342 | 0.78 | ILK (0.51) | ILKMAPT | |
| SCHEMBL5755318 | 0.78 | MAPK1 (0.60) | APPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539723-B1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-24 | — | — | EP | claimed |
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ASTRAZENECA (SE) | 2006-05-18 | — | — | US | claimed |
| EP-1539723-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | claimed |
| WO-2004016600-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | claimed |
| EP-1539723-B1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ASTRAZENECA (SE) | 2006-05-18 | — | — | US | disclosed |
| EP-1539723-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016600-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ITK, WEE2, WEE1 | APP 3980/4885ILK 1798/4885SULT1A1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.